Jade Biosciences, Inc. Increase Decrease In Operating Lease Liability
Jade Biosciences, Inc. (JBIO) reported Increase Decrease In Operating Lease Liability of -$59.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2026-08-10
- Jade Biosciences, Inc. increase decrease in operating lease liability for the quarter ending 2026-06-30 was -$30.00K.
- Jade Biosciences, Inc. increase decrease in operating lease liability for the quarter ending 2026-03-31 was -$29.00K, a 422.22% decline year-over-year.
- Jade Biosciences, Inc. increase decrease in operating lease liability for the quarter ending 2025-12-31 was -$28.00K.
- Jade Biosciences, Inc. increase decrease in operating lease liability for the quarter ending 2025-03-31 was $9.00K.
- Jade Biosciences, Inc. increase decrease in operating lease liability for fiscal 2025 was $40.00K.
| Period end | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 6 month | Increase Decrease In Operating Lease Liability 9 month | Increase Decrease In Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$30.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | -$59.00K 10-Q · filed 2026-08-10 | -$87.00K derived: sum of 3 quarters · filed 2026-08-10 | |
| 2026-03-31 | -$29.00K 10-Q · filed 2026-05-07 | -$57.00K derived: sum of 2 quarters · filed 2026-05-07 | ||
| 2025-12-31 | -$28.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-06 | $40.00K 10-K · filed 2026-03-06 | ||
| 2025-09-30 | $68.00K 10-Q · filed 2025-11-14 | |||
| 2025-03-31 | $9.00K 10-Q · filed 2026-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |